Figure 2: Competitive dynamics of the global top 10 biotech market, 2009 33

Figure 3: Roche's SWOT analysis 50

Figure 4: R&D pipeline by therapeutic area focus and development stage, 2010 57

Figure 5: Amgen's SWOT analysis 62

Figure 6: Gilead's R&D pipeline by therapeutic area focus and development stage, 2010 72

Figure 7: Gilead's SWOT analysis 77

Figure 8: UCB's R&D pipeline by therapeutic focus and development stage, 2010 86

Figure 9: UCB's SWOT analysis 92

Figure 10: Biogen Idec's pipeline by R&D focus and development stage, 2010 100

Figure 11: Biogen Idec's SWOT analysis 106

Figure 12: Genzyme's R&D pipeline by therapeutic area focus and development stage, 2010 116

Figure 13: Genzyme's SWOT analysis 123

Figure 14: Cephalon's R&D pipeline by therapeutic area focus and development stage, 2010132

Figure 15: Cephalon's SWOT analysis 136

Figure 16: CSL's SWOT analysis 147

Figure 17: Celgene's R&D pipeline by therapeutic area focus and development stage, 2010 155

Figure 18: Celgene's SWOT analysis 161

Figure 19: Amylin's pipeline by therapeutic area focus and development stage, 2010 168

Figure 20: Amylin's SWOT analysis 173

Table of tables

Table 1: The global biotechnology market by therapeutic class, 2009 30

Table 2: Top 10 players in the global biotech market, 2009 32

Table 3: Roche's sales by leading drug class, 2009 36

Table 4: Leading brands in Roche's product portfolio, 2009 37